Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 147

Cited In for PubMed (Select 11242107)

1.

The Potential of Vitamin D-Regulated Intracellular Signaling Pathways as Targets for Myeloid Leukemia Therapy.

Gocek E, Studzinski GP.

J Clin Med. 2015 Mar 25;4(4):504-34. doi: 10.3390/jcm4040504. Review.

2.

Molecular Genetic Markers in Acute Myeloid Leukemia.

Yohe S.

J Clin Med. 2015 Mar 12;4(3):460-78. doi: 10.3390/jcm4030460. Review.

3.

Drugging the unfolded protein response in acute leukemias.

Kharabi Masouleh B, Chevet E, Panse J, Jost E, O'Dwyer M, Bruemmendorf TH, Samali A.

J Hematol Oncol. 2015 Jul 16;8:87. doi: 10.1186/s13045-015-0184-7.

4.

The +37 kb Cebpa Enhancer Is Critical for Cebpa Myeloid Gene Expression and Contains Functional Sites that Bind SCL, GATA2, C/EBPα, PU.1, and Additional Ets Factors.

Cooper S, Guo H, Friedman AD.

PLoS One. 2015 May 4;10(5):e0126385. doi: 10.1371/journal.pone.0126385. eCollection 2015.

5.
6.

Data-driven prediction and design of bZIP coiled-coil interactions.

Potapov V, Kaplan JB, Keating AE.

PLoS Comput Biol. 2015 Feb 19;11(2):e1004046. doi: 10.1371/journal.pcbi.1004046. eCollection 2015 Feb. Erratum in: PLoS Comput Biol. 2015 Apr;11(4):e1004243.

7.

Contrasting roles for C/EBPα and Notch in irradiation-induced multipotent hematopoietic progenitor cell defects.

Fleenor CJ, Rozhok AI, Zaberezhnyy V, Mathew D, Kim J, Tan AC, Bernstein ID, DeGregori J.

Stem Cells. 2015 Apr;33(4):1345-58. doi: 10.1002/stem.1936.

PMID:
25546133
8.

Double CEBPA mutations are prognostically favorable in non-M3 acute myeloid leukemia patients with wild-type NPM1 and FLT3-ITD.

Wen XM, Lin J, Yang J, Yao DM, Deng ZQ, Tang CY, Xiao GF, Yang L, Ma JC, Hu JB, Qian W, Qian J.

Int J Clin Exp Pathol. 2014 Sep 15;7(10):6832-40. eCollection 2014.

9.

Divergent gene activation in peripheral blood and tissues of patients with rheumatoid arthritis, psoriatic arthritis and psoriasis following infliximab therapy.

Rosenberg A, Fan H, Chiu YG, Bolce R, Tabechian D, Barrett R, Moorehead S, Baribaud F, Liu H, Peffer N, Shealy D, Schwarz EM, Ritchlin CT.

PLoS One. 2014 Oct 21;9(10):e110657. doi: 10.1371/journal.pone.0110657. eCollection 2014.

10.

Clinical relevance of mutant NPM1 and CEBPA in patients with acute myeloid leukaemia - preliminary report.

Helbig G, Wozniczka K, Wieclawek A, Soja A, Bartkowska-Chrobok A, Kyrcz-Krzemien S.

Contemp Oncol (Pozn). 2014;18(4):241-5. doi: 10.5114/wo.2014.43490. Epub 2014 Aug 30.

11.

Identification of a dynamic core transcriptional network in t(8;21) AML that regulates differentiation block and self-renewal.

Ptasinska A, Assi SA, Martinez-Soria N, Imperato MR, Piper J, Cauchy P, Pickin A, James SR, Hoogenkamp M, Williamson D, Wu M, Tenen DG, Ott S, Westhead DR, Cockerill PN, Heidenreich O, Bonifer C.

Cell Rep. 2014 Sep 25;8(6):1974-88. doi: 10.1016/j.celrep.2014.08.024. Epub 2014 Sep 18.

12.

Long-term follow-up of cytogenetically normal CEBPA-mutated AML.

Pastore F, Kling D, Hoster E, Dufour A, Konstandin NP, Schneider S, Sauerland MC, Berdel WE, Buechner T, Woermann B, Braess J, Hiddemann W, Spiekermann K.

J Hematol Oncol. 2014 Sep 10;7:55. doi: 10.1186/s13045-014-0055-7.

13.

Prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group.

Matsuo H, Kajihara M, Tomizawa D, Watanabe T, Saito AM, Fujimoto J, Horibe K, Kodama K, Tokumasu M, Itoh H, Nakayama H, Kinoshita A, Taga T, Tawa A, Taki T, Tanaka S, Adachi S.

Blood Cancer J. 2014 Jul 11;4:e226. doi: 10.1038/bcj.2014.47.

14.

Pten regulates homeostasis and inflammation-induced migration of myelocytes in zebrafish.

Dong ZW, Ren CG, Xia Y, Su D, Du TT, Fan HB, Yuan H, Wang L, Dong M, Li WC, Jin Y, Chen Y, Deng M, Liu TX, Gu AH, Zhou Y.

J Hematol Oncol. 2014 Mar 5;7:17. doi: 10.1186/1756-8722-7-17.

15.

C/EBPα: critical at the origin of leukemic transformation.

Roe JS, Vakoc CR.

J Exp Med. 2014 Jan 13;211(1):1-4. doi: 10.1084/jem.20132530. Epub 2014 Jan 6. Review.

16.

Sox4 is a key oncogenic target in C/EBPα mutant acute myeloid leukemia.

Zhang H, Alberich-Jorda M, Amabile G, Yang H, Staber PB, Di Ruscio A, Welner RS, Ebralidze A, Zhang J, Levantini E, Lefebvre V, Valk PJ, Delwel R, Hoogenkamp M, Nerlov C, Cammenga J, Saez B, Scadden DT, Bonifer C, Ye M, Tenen DG.

Cancer Cell. 2013 Nov 11;24(5):575-88. doi: 10.1016/j.ccr.2013.09.018. Epub 2013 Oct 31. Erratum in: Cancer Cell. 2014 Feb 10;25(2):257. Diruscio, Annalisa [corrected to Di Ruscio, Annalisa].

17.

The gene signature in CCAAT-enhancer-binding protein α dysfunctional acute myeloid leukemia predicts responsiveness to histone deacetylase inhibitors.

Liss A, Ooi CH, Zjablovskaja P, Benoukraf T, Radomska HS, Ju C, Wu M, Balastik M, Delwel R, Brdicka T, Tan P, Tenen DG, Alberich-Jorda M.

Haematologica. 2014 Apr;99(4):697-705. doi: 10.3324/haematol.2013.093278. Epub 2013 Oct 25.

19.

The tumor suppressor gene DAPK2 is induced by the myeloid transcription factors PU.1 and C/EBPα during granulocytic differentiation but repressed by PML-RARα in APL.

Humbert M, Federzoni EA, Britschgi A, Schläfli AM, Valk PJ, Kaufmann T, Haferlach T, Behre G, Simon HU, Torbett BE, Fey MF, Tschan MP.

J Leukoc Biol. 2014 Jan;95(1):83-93. doi: 10.1189/jlb.1112608. Epub 2013 Sep 13.

20.

Transcription factor C/EBPα-induced microRNA-30c inactivates Notch1 during granulopoiesis and is downregulated in acute myeloid leukemia.

Katzerke C, Madan V, Gerloff D, Bräuer-Hartmann D, Hartmann JU, Wurm AA, Müller-Tidow C, Schnittger S, Tenen DG, Niederwieser D, Behre G.

Blood. 2013 Oct 3;122(14):2433-42. doi: 10.1182/blood-2012-12-472183. Epub 2013 Aug 23.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk